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Abstract
Binding of ligand FasL to its receptor Fas triggers apoptosis via the caspase cascade. FasL itself is homotrimeric, and
a productive apoptotic signal requires that FasL be oligomerized beyond the homotrimeric state. We generated a series of
FasL chimeras by fusing FasL to domains of the Leukemia Inhibitory Factor receptor gp190 which confer homotypic
oligomerization, and analyzed the capacity of these soluble chimeras to trigger cell death. We observed that the most
efficient FasL chimera, called pFasL, was also the most polymeric, as it reached the size of a dodecamer. Using a cellular
model, we investigated the structure-function relationships of the FasL/Fas interactions for our chimeras, and we
demonstrated that the Fas-mediated apoptotic signal did not solely rely on ligand-mediated receptor aggregation, but also
required a conformational adaptation of the Fas receptor. When injected into mice, pFasL did not trigger liver injury at
a dose which displayed anti-tumor activity in a model of human tumor transplanted to immunodeficient animals,
suggesting a potential therapeutic use. Therefore, the optimization of the FasL conformation has to be considered for the
development of efficient FasL-derived anti-cancer drugs targeting Fas.
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Introduction
FasL (CD95L) is a type II homotrimeric transmembrane protein
of the Tumor Necrosis Factor family of cytokines [1]. FasL is
expressed on activated T lymphocytes and natural killer cells, as
a weapon to eliminate transformed and infected cells expressing
the transmembrane receptor Fas (CD95/APO-1) [2]. The
triggering of Fas initially appeared as a promising approach to
treat cancer but an agonistic anti-Fas antibody triggered fulminant
lethal hepatitis upon injection in mice, precluding the use of Fas
inducers for a therapeutical purpose in human [3].
Cleavage of membrane-bound FasL by a metalloprotease [4,5]
generates soluble homotrimeric FasL (sFasL), which is weakly
apoptotic, and competes with membrane FasL for cell killing [6,7].
Interestingly, upon cross-linking with antibodies, sFasL recovers its
pro-apoptotic activity, and a FasL hexamer appears as the smallest
functional form [8]. Similarly, agonistic anti-Fas monoclonal
antibodies (mAbs) are mostly of the IgM or the self-aggregating
IgG3 isotypes.
Our general aims were to develop new isoforms of functional
FasL which do not require any crosslinking agent to become
cytotoxic, to use them for deciphering the functional requirements
leading to Fas activation, and to test them for in vivo anti-tumor
activity. To reach the first goal, we fused the ectodomain of FasL
to the modules of the extracellular domain of the LIF cytokine
receptor gp190 [9] which display a propensity to self-associate
[10,11]. The gp190 belongs to the family of the hematopoietin
receptors, characterized by the extracellular consensus Cytokine
Binding Domain (CBD). The gp190 harbors two CBDs (D1 and
D2) separated by an immunoglobulin-like (Ig) module. Therefore,
the trimeric structure of the sFasL moiety, combined to the
propensity of the gp190 modules to self-associate, could lead to
differently aggregated sFasL chimeras with distinct apoptotic
abilities.
To reach the second goal, we hypothesized that the distinct sizes
of the gp190 modules (i.e. around 20, 40 and 100 kDa for Ig, D2
and D1IgD2 respectively), could exert different steric effects,
distinctly impinging on the ability to trigger a productive apoptotic
signal independently of the polymerization of FasL. In addition,
given that Fas activation requires oligomers beyond the trimeric
stage, we reasoned that either aggregation of the trimers, or
a particular conformational change within a single trimer triggered
by a polymeric ligand, or both, is mandatory. Therefore, we
wondered whether anti-Fas antibody, naturally occurring sFasL
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and our chimeras, would be able to stimulate a chimeric Fas
receptor which would only require dimerization to transmit
a signal, and whether or not this property would correlate with the
ability to trigger cell apoptosis. To explore this possibility, we used
the gp130 signal transducing cytokine receptor, another member
of the hematopoietin receptors, which is pre-assembled as dimers
[12] and requires a ligand-induced conformational change to
become activated. Gp130 triggers cytokine-dependent prolifera-
tion of various cell lines via the Jak-STAT pathway [13]. We fused
transmembrane and intracellular regions of gp130 to the
extracellular region of Fas, generating the Fas-gp130 receptor,
and expressed it in the BA/F3 cell line.
To reach our third goal, in vivo toxicity in normal mouse, and
ability to counteract tumor development in a model of human
solid tumor transplanted into immunodeficient mice were
explored for our most efficient sFasL chimera.
Materials and Methods
Antibodies and reagents
Anti-FasL mAb 14C2 and 10F2 used for the FasL ELISA
[14], IgG anti-human Fas mAb 5D7 [14], isotype-matched
negative controls 1F10 (IgG) and 10C9 (IgM) mAbs [15] were all
generated in the laboratory. Chimeric Fas-Fc receptor was
produced in the laboratory and was affinity-purified on protein
A. Anti-FasL mAb (G247) used for immunoblots and anti-human
Fas non agonistic mAb DX2 were purchased from BD
Biosciences (Le-Pont-De-Claix, France). Recombinant sFasL
(recFasL) was purchased from Alexis Corporation (Coger, Paris,
France), and used with its cross-linking ‘‘enhancer’’ reagent, as
recommended by the manufacturer. Anti-human Fas agonistic
mAb 7C11 (IgM) was from Immunotech (Marseille, France).
Anti-murine Fas agonistic mAb (JO2) was from Bender
MedSystems (Vienna, Austria).
Construction of the FasL chimeras
The isolation of the gp190 receptor modules Ig, D2 and
D1IgD2 (amino acids 246 to 328, 329 to 542 and 49 to 542), was
described previously [10]. They were fused to the extracellular
domain of hFasL (amino acids 108 to 281) isolated by PCR. To
avoid confusion with the immunoglobulin Fc fragment, the
IgFasL chimera is called pFasL for polymeric soluble FasL. To
generate the Fas-gp130 chimera, the Fas extracellular region and
the transmembrane and intracellular domains of gp130 were
isolated by site-directed mutagenesis and fused together. All the
constructs were subcloned into the pED4 eukaryotic expression
vector [16].
Cell lines and transfections
The cells were grown in a 5% CO2 incubator at 37uC without
antibiotics in medium supplemented with 8% FCS (Sigma, Saint-
Quentin-Fallavier, France). Culture medium was RPMI for the
human Jurkat T-lymphoma and the BA/F3 pro-B-lymphocytic
murine cell lines, and DMEM for the human skin carcinoma A431
and the simian epithelial COS cell lines.
COS cells were transiently transfected using the DEAE-dextran
method, with 5 mg of plasmid DNA, and supernatants were
harvested 5 days later. Large scale production of pFasL was
performed in serum-free Opti-MEM medium (Fischer Scientific,
Illkirch, France).
The BA/F3 culture medium was supplemented with 10%
WEHI cell-conditioned medium as a source of murine interleukin
(IL)-3. BA/F3 cells (5.106 cells in 0.3 ml) were electroporated
(BTM 830 electroporator, BTX Instruments, Holliston, MA).
G418 at 1 mg/ml (Invitrogen) was added at day 1. The G418-
resistant cells were cloned by limiting dilution in the presence of
murine IL-3. Stable transfectants were selected for membrane
expression of the Fas-gp130 molecule by flow cytometry with the
anti-Fas antibody 5D7. BA/F3 cells were washed three times to
remove IL-3, then incubated with the indicated ligands, and
proliferation was estimated using the MTT proliferation assay
after 3 days, as described previously [10]. The maximum value
and the blank value were obtained with a saturating concentration
of IL-3 or without IL3, respectively.
The BA/F3, Jurkat, COS and A431 cell lines were obtained
respectively in 1991, 1995, 1992 and 2004 from Drs D’Andrea
[17], Anderson [18], Kaufman [19] and Nagata [20]. They were
mycoplasma-tested every 6 months by PCR [21] and Hoechst
33258 staining [22]. Absence of cross-contamination was verified
almost daily by morphology check for all the cell lines, and by
growth curve analysis in the presence and absence of IL-3 for the
BA/F3 cell line.
ELISA for sFasL
FasL was quantified in cell culture supernatants using a confor-
mation-dependent home made sandwich ELISA based on non-
blocking mAb 14C2 (10 mg/ml) as a capture antibody and
blocking biotinylated mAb 10F2 (1 mg/ml) as a tracer. All steps
were performed exactly as reported for our anti-human LIF
ELISA [23].
Western blot analysis
Supernatants from transfected cells were harvested and debris
were removed by centrifugation. FasL was quantified and 100 ng
of the FasL protein were resuspended in 5x Laemmli buffer and
separated by SDS-PAGE on 12% gels. Proteins were transferred
to a polyvinyldifluoride membrane (Amersham, Buckinghamshire,
England) and immunoblots were performed as previously de-
scribed [24]. The anti-FasL mAb G247 (1 mg/ml) was incubated
overnight at 4uC. BN-PAGE was carried out as described by
Scha¨gger [25] with the following modifications. A separating 4–
18% w/v acrylamide linear gradient was used. Before loading,
1 mL of sample buffer (500 mM 6-amino-n-caproic acid, 5% w/v
Serva Blue G) was added to the sample. The gel was run overnight
at 4uC with 1 W. Thyroglobulin (669 kDa) and BSA (66 kDa)
were used as size standards (Sigma). FasL was detected using mAb
G247.
Surface plasmon resonance analysis of the FasL chimeras
binding to Fas
The experiments were carried out on a BIAcore 3000 optical
biosensor (GE healthcare, Chalfont, UK). The FasL chimeras
were produced as COS supernatants in Opti-MEM medium,
concentrated 100 times, dialyzed against PBS and sterilized by
filtration. Recombinant Fas-Fc (R&Dsystems, Minneapolis, MN)
was covalently coupled to a carboxymethyl dextran flow cell
(CM5, BIAcore) following the manufacturer’s recommendations.
The level of immobilization was 2,000 resonance units (RU).
Binding of the FasL chimeras was assayed at concentrations
ranging from 0.2 to 100 nM for IgFasL, 0.2 to 44 nM for cFasL,
0.2 to 37.5 nM for D2FasL, and 0.25 to 8 nM for D1IgD2FasL, in
Hepes-buffered saline, at a 30 ml/min flow rate. Association was
monitored for 5 min before initiating the dissociation phase for
another 11 min with Hepes-buffered saline. The flow cell was
regenerated with 4M MgCl2. The sensorgrams were analyzed
using the BIAeval 4.1 software (BIAcore). The background of the
Opti-MEM medium was at 30 RU.
Chimeric FasL with Anti-Tumor Activity
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Cell cytotoxicity assays
The cytotoxic activity of the FasL chimeras was measured using
the MTT viability assay as previously described, after 24 hours of
incubation with serial dilutions of the indicated ligands [14]. The
percent of specific cytotoxic activity of FasL was calculated as
follows: 100 – (experimental absorbance – background absor-
bance)/(control absorbance – background absorbance)6100.
Gel filtration experiments
The molecular size of the FasL constructs was determined using
the size exclusion S-200-HR and S-300-HR Sephacryl columns of
120 ml bed volume and 40 ml void volume (Amersham
Pharmacia, Orsay, France). COS supernatants were concentrated
with Centricon-30 (Millipore, Saint-Quentin-en-Yvelines, France)
to reach 2 mg/ml for each sFasL form. One microgram was loaded
onto a column and eluted in PBS at 0.3 ml/min. 80 Fractions of
0.8 ml were collected starting at 25–30 ml of elution, and were
analyzed for the presence of FasL protein by ELISA and for Fas-
mediated cytotoxicity using the MTT assay.
FasL purification and mice injection
Experiments with normal Balb/cByJCr1 mice used immunoaf-
finity purified pFasL. Supernatant from transfected COS cells
(500 mL) was immunoprecipitated using 1 ml of anti-FasL mAb
(14C2)-coupled NHS-activated sepharose beads (Amersham),
overnight at 4uC. Beads were pelleted and washed in PBS, and
pFasL was eluted at pH 2 (50 mM glycine, 1 M NaCl). The eluate
was immediately neutralized by adding 0.25 volume of 1 M Tris–
HCl buffer at pH 8. After overnight dialysis against PBS, FasL was
quantified by ELISA. Male BALB/cByJCr1 mice (8 wk old) were
injected intraperitoneally with 0.5 ml PBS containing 10 mg of
pFasL, or of anti-Fas agonistic mAb JO2, or with PBS alone.
Blood was collected at 6 and 30 h for liver enzymes measurement.
The mice were euthanasied at 30 h post-injection.
For tumor experiments, COS cells were transfected with pFasL
or empty vector as a control, and grown in Opti-MEM medium.
Supernatants were harvested at day 5, centrifuged, concentrated
60 times against polyethylene glycol flakes, adjusted to 0.1 mg/ml
and sterilized by filtration. Immunodeficient Rag2/2cc2/2 mice,
a gift from Dr Di Santo [26], were used at 7–10 weeks of age, and
housed in appropriate animal facility under pathogen-free
conditions. At day 0, mice received 105 A431 cells in 0.1 ml of
culture medium subcutaneously into the right flank. Injections of
pFasL (10 mg in 0.1 ml) or concentrated empty vector control
supernatant were performed after tumor implantation, either
subcutaneously at days 2 and 7, or intraperitoneally everyday
between days 0 and 7, then at days 9, 11 and 14. Tumor growth
was monitored by measuring maximal and minimal diameters
with a calliper, three times a week, and tumor volume was
estimated with the formula: tumor volume (mm3) = length (mm)6
width2 (mm) 60.5. The animal studies conducted in this report
have been reviewed and approved by the scientific committee
from the Bordeaux Segalen University’s animal facility. Experi-
mental work was performed by Dr Capone with agreement
reference C33 00 024. All efforts were made to minimize suffering.
Mice were euthanized at day 35, as no therapeutic effect of IgFasL
or control were expected any more at that point of tumor
evolution with the experimental design used. At this time point,
tumor volume remained below 1500 mm3.
Statistical analysis of tumor growth
The Mann-Whitney test was used for the comparison between
the two groups in the experiment with subcutaneous injection of
pFasL. The Kaplan-Meier analysis was used to establish the
survival curves without cancer, and comparison between the two
groups was made using the log-rank test. Analyses were performed
with Statview Software (Abacus Concepts, Berkeley, CA). For all
experiments, a p#0.05 was considered significant.
Results
Generation and production of soluble potentially
multimeric FasL/gp190 chimeras
We fused the Ig-like, D2 and D1IgD2 modules of gp190 to the
FasL extracellular region (Figures 1A and 1B). The constructs were
expressed in COS cells and the secreted molecules were quantified
using a FasL-specific ELISA. To measure their ability to trigger
cell death, we incubated serial dilutions of the supernatants from
chimeric FasL, control mock-transfected and wild-type FasL
transfected cells with Fas-sensitive Jurkat cells. A commercially
available FasL (recFasL) was also tested as a highly active
reference. The pFasL was the strongest death inducer among
our chimeras and was as powerful as recFasL (Figure 1C). D2FasL
and D1IgD2FasL were respectively 12.5 and 125 times less potent
than pFasL. As already known, spontaneously cleaved membrane
FasL (cFasL) had almost no activity [6,7]. The concentration of
the anti-Fas agonistic IgM antibody 7C11 required to kill 50% of
the Jurkat cells was at 2 ng/ml (results not shown) [14,24,27].
Biochemical characterization of the FasL/gp190 chimeras
Identical amounts of the 35S-labeled FasL constructs were
separated by SDS-PAGE (Figure 2A, left panel) and the molecular
mass of each chimera was determined under reducing conditions
(Figure 2D). We also performed native gel electrophoresis (BN-
PAGE) in non-reducing conditions (Figure 2A, right panel), and
observed that pFasL, D2FasL and D1IgD2FasL all displayed
much higher molecular weights than expected from the SDS-
PAGE analysis (Figure 2D). The three chimeras were also
analyzed by gel filtration chromatography (Figure 2B). Elution
fractions were analyzed for the presence of FasL by ELISA
(Figure 2B, upper panel) and for cytotoxic activity against the
Jurkat cell line (Figure 2B, lower panel). We confirmed that the
metalloprotease-cleaved FasL is a non cytotoxic homotrimer,
whereas D2FasL and D1IgD2FasL behaved as hexamers. In
contrast to D2FasL, D1IgD2FasL was very weakly cytotoxic, in
agreement with Figure 1C. The pFasL existed under two distinct
forms corresponding to a high molecular weight dodecamer and to
a smaller hexameric form. Both were cytotoxic, which is consistent
with previously published results for soluble FasL in the case of the
hexamer [8].
The affinity of the FasL chimeras for Fas was measured using
the surface plasmon resonance BiacoreH method, against recom-
binant Fas-Fc immobilized on a chip. D2FasL, D1IgD2FasL
pFasL and sFasL as a control, were produced as supernatants in
COS cells cultured in serum-free medium, concentrated
100 times, and dialysed against PBS. The sensorgrams are
depicted in Figure 2C and the association and dissociation
constants are presented in Table 1. The Kd for the three chimeras
were very close to each other, ranging from 11.6 nM for pFasL, to
25.6 nM for D1IgD2FasL and to 38.5 nM for D2FasL. They were
inversely correlated with the degree of polymerisation of the
construct, and two to six times higher than for non-chimeric cFasL
(Kd = 69.4 nM). Therefore, the small differences between the
chimeras did not significantly alter the ability of the FasL moiety to
bind to Fas, nor did it explain the strong discrepancies in their
abilities to trigger apoptosis.
Chimeric FasL with Anti-Tumor Activity
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FasL chimeras and agonistic antibody differentially act on
Fas conformation
To determine whether a conformational change in the Fas
receptor is required to produce the apoptotic signal, we generated
a fusion protein between the extracellular region of Fas and the
transmembrane and intracellular region of the gp130 hemato-
poietin receptor (Figure 3A) which we expressed in the IL-3
dependent BA/F3 murine cell line. This cell line relies on
exogenously added cytokines to survive and proliferate, and also
lacks membrane expression of murine Fas as shown by flow
cytometry staining with the JO2 antibody (Figure 3B, upper
panel). In the presence of FasL, stable expression of the chimera
was expected to keep the cells proliferating through the activation
of the gp130 pathway. The membrane expression of the Fas-
gp130 chimera was verified using flow cytometry, and the absence
of murine Fas on the transfectants was confirmed (see Figure 3B,
lower panel, for the representative clone used in the proliferation
experiments). In the absence of IL-3, the BA/F3 Fas-gp130 cells
did not proliferate, demonstrating that the Fas-gp130 chimera by
itself was not able to sustain cell growth (Figure 3C).
We then analyzed the effect on cell survival and proliferation of
serial dilutions of the 7C11 agonistic anti-Fas antibody, of the FasL
chimeras, and of cFasL (Figure 3C). Cell viability was expressed as
the percentage of the maximal proliferation triggered by
a saturating concentration of IL-3. We observed that the strongly
apoptotic 7C11 mAb was not able to sustain cell proliferation. In
contrast, the pro-apoptotic pFasL and D2FasL triggered a strong
and quantitatively comparable proliferative signal, although
D2FasL was 12.5 times less efficient than pFasL for killing the
Jurkat cells (see Figure 1C). D1IgD2-FasL, which is hexameric like
D2FasL but only weakly triggers cell death (see Figure 1C), was
unable to sustain cell proliferation. The non apoptotic homotrimer
cFasL which is unable to aggregate the pre-associated Fas
homotrimers and as such is not cytotoxic, nevertheless triggered
a proliferative signal comparable to that of D2FasL and IgD2FasL.
The discrepancy between the polymeric apoptotic antibody 7C11
and the trimeric cFasL demonstrated that the proliferative signal
did not require Fas aggregation, and suggested that the triggering
of Fas may also include a ligand-induced conformational change
of the receptor itself.
Anti-tumor activity of pFasL
The pFasL chimera exerted its cytotoxic activity against various
human tumor cell lines from distinct origins, both hematopoietic
(CEM and H9 T-lymphoma cells, SKW6.4 and JY B-lymphoma
cells, with C50 ranging from 0.01 to 0.1 mg/ml), and non-
hematopoietic (A431 epidermoid carcinoma cells, which was
weakly sensitive, with C50= 0.15 mg/ml) (results not shown). We
observed for these cell lines differences in efficiency of the
apoptotic activity that were similar to pFasL, with the different
chimeras (results not shown), demonstrating that the distinct
behaviors of these chimeric proteins were independent of the cell
type.
To determine the hepatotoxicity of pFasL, we injected the
ligand in mice and we analyzed in peripheral blood the markers of
liver injury aspartate amino transferase (ASAT) and alanine amino
Figure 1. Obtention and functional characteristics of the FasL/gp190 chimeras. Panel A: Modules constituting gp190 and FasL are
depicted as mature proteins. EC, TM and IC represent the extracellular, transmembrane and intracellular domains, respectively. N and C represent the
N- and C-terminal ends. The numbers depict the domain boundaries used to create the chimeras. Cleaved FasL (cFasL) is spontaneously generated by
a metalloprotease cleaving between aminoacids 126 and 127. Panel B: Representation of the cFasL and the gp190/FasL chimeras. Panel C: Serial
dilutions of supernatants from COS cells transfected with the FasL constructs or the empty vector (control) were incubated with Jurkat cells. Cell
death was measured using the MTT assay. As a positive control, we used the commercially available antibody-cross-linked FasL (recFasL). Calculated
C50 are indicated on the graph. Results from one representative experiment out of 5 are depicted.
doi:10.1371/journal.pone.0054000.g001
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transferase (ALAT). Mice were injected intraperitoneally with
10 mg (0.7 mg/g) of affinity-purified pFasL diluted in PBS. As
controls, one mouse was injected with an identical volume of PBS
and another one was left untreated. As a positive control, two mice
were injected intraperitoneally with 10 mg of the agonistic anti-
murine Fas antibody JO2 in the same volume of PBS. One of these
mice developed a fulminant hepatitis and was sacrificed 6 hours
after antibody injection. The anti-Fas JO2 mAb triggered a rapid
and considerable increase of both serum amino transferases,
whereas sera from the negative control mice and mice injected
with the purified pFasL did not show any sign of liver cytolysis
(Table 2).
The anti-tumor activity of pFasL was estimated in a mouse
model, using the weakly Fas-sensitive human A431 cells
transplanted subcutaneously to Rag2/2 cc2/2 immunodeficient
mice. In a first experiment (Figure 4A), we analyzed whether
pFasL injected locally would control tumor growth. For that, 105
A431 cells were injected to two groups of 6 mice. Then the mice
received two local subcutaneous injections of either pFasL (a non
toxic amount of 10 mg in the form of a serum-free concentrated
supernatant) or pFasL-free control, at days 2 and 7 after tumor
implantation. Tumor growth was regularly measured until day 21,
and the evolution of tumor volumes is depicted in Figure 4A. The
local administration of pFasL significantly reduced tumor growth,
in comparison to the mice injected with the control without pFasL,
Figure 2. Biochemical characterization of the FasL/gp190 chimeras. Panel A: Supernatants from COS cells transfected with the FasL
constructs were quantified by ELISA and 10 mg of FasL protein were loaded per lane. Migrations were performed under reducing (SDS-PAGE) or non-
reducing (BN-PAGE) conditions. FasL was revealed by immunoblot. Panel B: 2 mg of FasL construct were loaded on the gel filtration column. FasL
was quantified by ELISA in elution fractions, and cytotoxicity was measured using the MTT assay. Panel C: Affinity measurement using BiacoreH. Fas-
Fc was immobilized on the chip, before the indicated soluble FasL constructs were added. A range of concentrations was tested for each analyte, but
only the graph obtained with the highest concentration tested is displayed. Panel D: The apparent molecular weights and degree of oligo/
polymerization of the FasL chimeras were estimated from the non denaturing gel electrophoresis and gel filtration experiments.
doi:10.1371/journal.pone.0054000.g002
Table 1. Association/dissociation constants of the soluble
FasL chimeras.
Ligand Kon (1/Ms) Koff (1/s) KD (M) Chi2
D1IgD2FasL 1.36105 3.361023 2.5661028 8.34
D2FasL 1.66105 6.061023 3.8561028 3.37
pFasL 2.56104 4.161024 1.1661028 2.75
cFasL 8.46104 5.961023 6.9461028 16
doi:10.1371/journal.pone.0054000.t001
Chimeric FasL with Anti-Tumor Activity
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but the effect vanished when the injections were stopped. We next
analyzed whether injection of pFasL at a distance from the tumor
site would have a similar effect. For that, 105 A431 cells were
injected to two groups of 10 mice, and two independent
experiments were performed. The mice received intraperitoneal
injections of either pFasL (10 mg) or pFasL-free control, everyday
from day 0 to day 7, and thereafter at days 9, 11 and 14 only.
Tumor size was measured regularly until day 35. The percentage
of mice without detectable tumor is presented in Figure 4B, and
shows that pFasL is able to significantly (p = 0.02) lower tumor
growth, as 25% of the mice having received pFasL remain tumor-
free at a time where the control mice having received medium
alone all displayed tumor development. Therefore, these in vivo
preliminary experiments demonstrate that the in vitro biological
properties of pFasL are conserved in vivo.
Discussion
The pFasL, D2FasL and D1IgD2FasL chimeras allowed us to
analyze the structure-function relationships enabling FasL to
activate Fas. The cytotoxic activity strongly depended on both the
polymerization level of the chimera and the size of its constitutive
monomers, more than on the affinity for Fas, which was very close
for all three. Indeed, the most efficient construct was pFasL, i.e.
the most polymeric (dodecameric) but also the shortest one at the
monomeric level. However, it is noteworthy that hexameric
D1IgD2FasL was 10 times less cytotoxic than hexameric D2FasL,
suggesting that the polymerization degree is not the only
parameter to be important. In line with this, the IgM agonistic
antibody 7C11 displays ten potential binding sites for Fas, and
therefore should behave closely to the dodecameric pFasL.
However, we previously demonstrated that pFasL can trigger
apoptosis in cells harboring a mutation in the Fas death domain at
the hemizygous state, which were completely insensitive to the
agonistic antibody [24]. Therefore, our results confirmed that the
extent of FasL oligomerization is essential but not sufficient for
triggering the apoptotic signal. We therefore hypothesized that
a Fas conformational change might be required as well.
We explored this possibility with the cellular assay using the Fas-
gp130 chimeric receptor. Trimeric cFasL, pFasL and hexameric
D2FasL efficiently triggered proliferation, but hexameric D1IgD2-
FasL did not. It is possible that the voluminous D1IgD2 domain
impairs the conformational change in the gp130 domain while
maintaining Fas binding. This could similarly explain why it lacks
cytotoxicity towards wild-type Fas. The agonistic anti-Fas antibody
is also unable to trigger cell proliferation through Fas-gp130,
although it efficiently triggers apoptosis [14,27]. As for
D1IgD2FasL, this could be explained by structural constraints
due to the IgM isotype. The apoptotic effect of the IgM mAb
would then result from a large aggregation of Fas trimers, leading
to caspase activation. In line with this, the non apoptotic cFasL is
Figure 3. FasL/gp190 chimeras and agonistic antibodies differentially act on Fas conformation. Panel A: Description of the model used
to analyze the requirement for a Fas conformational change during its activation. The Fas-gp130 hybrid receptor is stably expressed in the IL-3
dependent BA/F3 cell line. Panel B: Cell surface staining of parent BA/F3 cells (upper panel) and on a representative clone stably expressing the Fas-
gp130 chimera (lower panel), with an isotype-matched control (dotted line), anti-murine Fas JO2 (dashed line) and anti-human Fas DX2 (continuous
line). Living cells were gated on the basis of the morphological parameters. Panel C: Fas-gp130 BA/F3 cells were incubated with the indicated Fas
triggers or controls, and proliferation was measured using a MTT assay. Results are expressed as percentages of the maximum proliferation obtained
with a saturating IL-3 concentration. Proliferation of parent and transfected cells was also measured in the absence of any IL-3 or Fas trigger. Values
are the mean 6 sd of 3 independent experiments.
doi:10.1371/journal.pone.0054000.g003
Table 2. pFasL does not induce liver damage.
Fas trigger ASAT (IU/ml) ALAT (IU/ml)
6 hours 30 hours 6 hours 30 hours
Control (no PBS) 66 48 43 27
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1mice were injected with the indicated ligands as described in Materials and
Methods. Blood samples were harvested at the indicated time points and the
levels of alanine amino transferase (ALAT) and aspartate amino transferase
(ASAT) were measured in the serum.
2not determined, euthanised before reaching time point.
doi:10.1371/journal.pone.0054000.t002
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expected to trigger strong cell proliferation, because it is the Fas
natural ligand and as such must display the best fit for this
receptor. As pFasL is capable of triggering the adequate Fas
conformational change and is also polymeric, this would therefore
explain why it can kill cells which normally resist to the agonistic
antibodies [24]. These results overall confirm our reported finding
that FasL and antibodies do not stimulate identically the Fas
signalling machinery [27], and confirm the requirement of
minimal Fas aggregation by a multimeric ligand trigger [8]. In
addition, a recent work brought into the landscape the theory of
the T-cell receptor serial triggering and applied it to Fas, by clearly
demonstrating that there is an inverse correlation between
agonistic antibody affinity and potency [28]. According to these
authors, the antibodies with the highest affinity for Fas do not
efficiently trigger apoptosis by remaining blocked on the receptors
they bound to, precluding the formation of higher order receptor
aggregates able to transmit the apoptotic signal. Our findings on
the FasL chimeras are not contradictory to these results, although
we observed drastic differences that could not be explained by
affinity differences for Fas. On the contrary, our results strengthen
the notion that Fas agonistic antibodies and FasL-derived agonists
display intrinsic major peculiarities in their respective modes of
action, which have to be considered for a therapeutic application
in human.
The pFasL chimera demonstrated a very potent apoptotic
activity, in the absence of any cross-linking enhancing agent. Using
experiments in mouse, we detected no liver damage after
intravenous injection. Although these findings seem in contradic-
tion with data showing that Fas engagement in mice induce an
acute liver injury, it is noteworthy that these reports used in fact
the anti-Fas JO2 agonistic antibody and not FasL [3,29,30,31,32].
The liver destruction observed following injection of anti-Fas
antibodies may simply be the consequence of an antibody-
dependent cell-mediated cytotoxicity reaction [33], as the pro-
duction of inflammatory cytokines by Fc receptor–bearing Kupffer
cells has been observed [34]. In addition, our results confirm
another report, which showed that injection of a polymeric
leucine-zipper chimeric FasL in rats only triggered a mild liver
damage [35]. Therefore, we predict that all forms of polymeric
FasL which would depend on antibody-mediated cross-linking will
be toxic. Using a transplanted human tumor mouse model, we
then demonstrated an anti-tumor effect of a non-toxic dose of
pFasL, administered several times, locally or intraperitoneally at
a distance from the tumor site. Therefore, pFasL also demon-
strated in vivo activity, by reducing tumor development. In-
terestingly, the A431 human epidermoid carcinoma cell line we
used naturally displays only weak sensitivity to FasL-induced
apoptosis when compared to the human lymphoid cell lines we
tested. Although more experiments and higher doses are still
required to better describe pFasL toxicity and activity, it appears
that for a future therapeutic use in cancer treatment, the design of
soluble FasL forms spontaneously reaching a high degree of
polymerization should also consider their ability to trigger the
adequate Fas receptor conformational adaptation.
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